...
首页> 外文期刊>The New Microbiologica >Carbapenemase-producing Enterobacteriaceae isolates resistant to last-line antibiotics in an Italian general hospital
【24h】

Carbapenemase-producing Enterobacteriaceae isolates resistant to last-line antibiotics in an Italian general hospital

机译:生产肠杆菌酶产生的肠杆菌区分离出意大利综合医院的最后一线抗生素的抗性

获取原文
获取原文并翻译 | 示例
           

摘要

The global dissemination of carbapenemase-producing Enterobacteriaceae (CPE) is of great concern for public health. These bacteria have the potential for rapid dissemination in healthcare settings and cause infections associated with high rates of morbidity and mortality. A total of 221 carbapenem non-susceptible Enterobacteriaceae isolates were collected from patients admitted to an Italian general hospital from January 2016 to March 2017. Among these isolates, 78.3% were carbapenemase producers: 96% were positive for the bla(KPC) gene and the remainder for the bla(VIM) gene (allelic variant VIM-1). CPE isolates were mainly Klebsiella pneumoniae, but we also detected carbapenemase enzymes in Citrobacter freundii, Enterobacter cloacae and Escherichia colt. Among CPE isolates, 79.2% exhibited co-resistance to two or more non-beta-lactam agents and 38% of these isolates (all KPC-positive) were resistant to colistin. This percentage reached 55% among CPE isolated from the bloodstream. All patients with colistin-resistant CPE isolates recovered from blood samples showed an unfavorable outcome within 7 days from the first positive blood culture. Our data show the dissemination of a high percentage of CPE isolates co-resistant to last-line antibiotics. In addition, we report the first identification in our hospital of CPE isolates harboring the bla(VIM) gene and Escherichia colt harboring the bla(KPC) gene. These results underline the need to implement antibiotic stewardship and infection control programs, and emphasize the need for novel antimicrobial agents active against CPE.
机译:产生碳碱酶的肠杆菌菌(CPE)的全球传播对公共卫生非常关切。这些细菌有可能在医疗保健环境中快速传播,并引起与发病率和死亡率高的感染。从2016年1月到2017年3月入院的患者中,共收集了221克巴彭烯烯肠道肠杆菌区分离株。这些分离株中,78.3%是碳结构生产商:96%对BLA(KPC)基因呈阳性阳性BLA(Vim)基因的剩余部分(等位基因变异Vim-1)。 CPE分离株主要是Klebsiella肺炎,但我们还发现了在酸薄杆菌的肠杆菌酶,肠杆菌肝硬化和大肠杆菌菌中检测到碳癌酶。在CPE分离物中,79.2%表现出与两个或更多个非β-内酰胺剂的耐抗抗性,其中38%的这些分离株(所有KPC阳性)对Colistin抵抗力。从血液中分离的CPE,这一百分比达到55%。所有耐药CPE的患者均从血液样品中恢复的分离株,从第一次阳性血液培养后7天内显示出不利的结果。我们的数据显示,高百分比的CPE分离物与最后一线抗生素的分离物的传播。此外,我们报告了我们患有BLA(Vim)基因的CPE分离物医院的第一次识别,含有BLA(KPC)基因的BLA(Vim)基因和大肠杆菌。这些结果强调了实施抗生素管道和感染控制计划的需要,并强调需要对CPE活跃的新型抗微生物剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号